Your Path to Hope Resources

In some cases, brain tumors can affect a person’s problem-solving abilities. This can happen due to the tumor itself or as a result of the effects of standard treatments such as chemotherapy or radiation. Rehabilitation …

About Us Brain tumors present unique challenges, demanding specialized care from diagnosis through treatment. With a shared commitment to addressing these challenges, the Brain Cancer Support and Solutions Alliance leverages the strengths of its member organizations to …

Glioblastoma multiforme (GBM) is the most common type of malignant (cancerous) brain tumor in adults. Cancer cells in GBM tumors rapidly multiply. The cancer can spread into other areas of the brain as well. Rarely, the cancer spreads outside the brain to other parts of the body. Glioma tumors like GBM start in glial cells. Glial cells are vital to nerve cell function. GBMs specifically form in glial cells called astrocytes. GBMs are the fastest-growing astrocytoma (tumor that forms in astrocytes). Types Healthcare providers use a grading system from 1 to 4 to indicate brain tumor growth.

Novocure was founded to provide patients with a new cancer treatment based on using alternating electric fields, when applied at specific frequencies, can disrupt cancer cell division and cause cancer cell death. This innovative treatment, Tumor Treating Fields, is a completely different approach to cancer therapy. What are TTFields?TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms.Electric fields have different effects on the human body depending on their frequency, leading to diverse applications in healthcare such as microwave ablation, deep brain stimulation, and pacemakers.

A brain tumor patient will encounter numerous specialists and need to make a multitude of decisions throughout their journey. With these factors and more, navigating cancer care can be overwhelming.  For patients with glioblastoma (GBM), management is even more challenging due to their poor prognosis, feelings of isolation, need for treatment, and cognitive decline associated with this rare and progressive disorder. For these reasons, shared decision-making (SDM) must be integrated into standard practice so that patients’ expectations and goals are considered when discussing and weighing the risks and benefits of treatments.

Dr. Khagi from UNC Neuro-Oncology Program breaks down a glioblastoma diagnosis from imaging to clinical trials to new research.